迈得医疗第二季度归母净利环比大幅扭亏 积极开拓隐形眼镜业务

Core Insights - The company reported a revenue of 141 million yuan and a net profit attributable to shareholders of 6.0451 million yuan for the first half of 2025, with a significant increase in net cash flow from operating activities by 243.9% year-on-year [1] - In the second quarter, the company achieved a revenue of 101 million yuan and a net profit of 16.8424 million yuan, marking a substantial turnaround from previous losses [1] Business Overview - The main business of the company includes the research, production, sales, and service of medical consumables and intelligent equipment, focusing on safety infusion and blood purification devices [1] - The company is actively expanding its second growth curve through its subsidiary, Zhejiang Maide Shun Contact Lens Co., Ltd., by advancing its contact lens business and developing related materials and products [1] Production Capacity and Strategy - The company currently operates four production lines for contact lenses, each with an annual capacity of 18 million pieces, and plans to dynamically adjust production capacity based on market conditions as the business commercializes [2] - The company has a unique advantage in production, as it manufactures its own equipment, allowing for continuous improvement and cost optimization, unlike competitors who must purchase equipment [2] Order and Contract Status - As of the end of 2024, the company has 21 orders for its drug-device combination products, which are expected to be a new growth point for performance [2] - The company's contract liabilities exceeded 180 million yuan in the first half of the year, representing an increase of 83.28% compared to the end of the previous year, indicating a rise in advance payments for orders [2]